Catherine Sinfield
Icahn School of Medicine at Mount Sinai
4 Papers
Catherine Sinfield is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Internal medicine & Renal function. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease
Joji Tokita,David Lam,Aida Vega,Stephanie Wang,Leonard Amoruso,Tamara Muller,Nidhi Naik,S. Rathi,Sharlene Martin,Azadeh Zabetian,Catherine Liu,Catherine Sinfield,Tony McNicholas,Fergus Fleming,Steven G Coca,Girish N Nadkarni,Roger Tun,Mike Kattan,Michael Donovan,Arshad K Rahim +19 more
TL;DR: Deployment and risk stratification by KidneyIntelX was associated with an escalation in action taken to optimize cardio-kidney-metabolic health including medications and specialist referrals to optimize cardio-kidney-metabolic health.
2
12-LB: Clinical Impact of Risk Profiling with KidneyIntelX on DKD Progression in a Large Integrated Health Care System
TL;DR: Kattan et al. as discussed by the authors reported the one-year pre and post-test clinical impact on eGFR slope and hemoglobin A1C (HbA1C) in the Mount Sinai Health System.
Assess Before Rx: Reducing the Overtreatment of Asymptomatic Blood Pressure Elevation in the Inpatient Setting.
Sara D. Pasik,Sophia Chiu,Jeong Yang,Catherine Sinfield,Nicole Zubizarreta,Rosemarie Ramkeesoon,Hyung J. Cho,Mona Krouss +7 more
TL;DR: A significant reduction in inappropriate use of IV antihypertensives and an associated reduction in adverse events was demonstrated.
Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes
Joji Tokita,Aida Vega,Catherine Sinfield,Nidhi Naik,S. Rathi,Sharlene Martin,Stephanie Wang,Leonard Amoruso,Azadeh Zabetian,Steven G. Coca,Girish N. Nadkarni,Fergus Fleming,Michael J. Donovan,Robert Fields +13 more
TL;DR: In this paper , the authors evaluated the impact of the use of a multiplex, bioprognostic, immunoassay consisting of three plasma biomarkers and clinical variables that uses machine learning to generate a risk score for progressive decline in kidney function over 5-year in adults with early-stage diabetic kidney disease.